Severe allergies identified by EU agency as side effect of Novavax COVID-19 vaccine

Published: Updated:
Read Mode
100% Font Size
1 min read

The European Medicines Agency on Thursday identified severe allergic reactions as potential side effects of Novavax Inc’s COVID-19 vaccine.

The vaccine was authorized by US regulators on Wednesday, and its product label in the United States warns against administering the shot to people with a history of allergic reactions to any components of the shot.

For the latest headlines, follow our Google News channel online or via the app.

The EMA said it would also update the product information for the vaccine to add unusual or decreased feeling in the skin as a new side effect.

Only 250,000 doses of Novavax’s COVID vaccine, Nuvaxovid, have been administered in Europe so far since its launch in December, according to the European Centre for Disease Prevention and Control.

Read more:

Japan warns of COVID-19 surge, PM Kishida to hold news conference

Fresh COVID-19 wave sweeps Asia

Long COVID-19 patients traveling abroad for unproven ‘blood washing’ treatment: Study

Top Content Trending